Project Grant K08CA301024
- Federal Project Grant Award Summary The University of Virginia received a $192,888 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), effective September 1, 2025, through August 31, 2028. This award supports research aimed at identifying causal genetic variants associated with colorectal cancer risk and elucidating their mechanistic pathways. The project employs normal colon organoids as a novel research platform to distinguish true...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Research Manpower program (CFDA 93.398), awarded a $131,099 Project Grant to The Leland Stanford Junior University, effective July 1, 2025 through June 30, 2027. This award supports a comprehensive investigation of the obesity paradox phenomenon in renal cell cancer (RCC), examining how adiposity-related factors at molecular, individual, and neighborhood levels influence RCC incidence, tumor aggressiveness,...
- Federal Grant Award Summary The National Cancer Institute awarded The Johns Hopkins University a $510,431 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2025 through June 30, 2030. This award supports fundamental research investigating the mechanisms of metastatic recurrence and therapeutic resistance in melanoma, with particular emphasis on understanding how aging influences tumor dormancy and the microenvironment. The research examines Wnt signaling...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $332,212 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) on September 10, 2025, with completion targeted for March 9, 2028. The award supports a research training and career development initiative focused on investigating sex hormone signaling in hepatocellular carcinoma (HCC). The project deliverables include comprehensive...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $185,760 to the University of Chicago under the Cancer Research Manpower program (CFDA 93.398) on September 15, 2025, for a research project titled "Targeting Glycerol Metabolism in Anti-Tumor Immunity." The award supports a three-year project (concluding August 31, 2028) investigating the mechanistic relationship between glycerol metabolism and CD8+ T cell function in the context of obesity-related...
- Federal Grant Award Summary Tufts University School of Medicine received a $883,825.75 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) on May 15, 2025. This research initiative leverages existing leukocyte deoxyribonucleic acid (DNA) methylation data to identify biological pathways linking obesity to 13 distinct cancer types. The project utilizes data from the Atherosclerosis Risk in Communities Study (ARIC) to...
- Federal Grant Award Summary The National Cancer Institute awarded $115,420 to the University of Virginia under the Cancer Research Manpower program (CFDA 93.398) on May 1, 2026, through a K99/R00 Pathway to Independence Award supporting Dr. Kelsey Day's career development as an independent investigator in community-based physical activity research and cancer prevention. During the K99 phase, Dr. Day will receive training in four key competency areas: text message and mobile health (mHealth)...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a Project Grant totaling $323,860 under the Cancer Research Manpower program (CFDA 93.398), effective August 18, 2025, with completion by April 30, 2028. This award supports investigative research to elucidate the role of mutagenic DNA repair mechanisms, specifically microhomology-mediated end joining (MMEJ), during cancer cell persistence and the development of acquired drug...
- Federal Grant Award Summary The National Cancer Institute awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant under the Cancer Research Manpower program (CFDA 93.398) in the amount of $123,182.00, effective July 17, 2025, with a completion date of June 30, 2027. This award supports a Pathway to Independence Award (K99/R00) research project investigating the mechanisms by which dormant disseminated breast cancer cells communicate with their surrounding...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts Institute of Technology (MIT) a project grant of $133,955 on August 7, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support cancer research training and investigation through July 31, 2027. The grant funds research examining how cancer cachexia—progressive wasting of skeletal muscle, fat, and other tissues observed in pancreatic ductal adenocarcinoma (PDAC) patients—influences...
The National Cancer Institute (NCI) awarded the University of Virginia a $291,498 Project Grant under the Cancer Research Manpower program (CFDA 93.398) on May 1, 2026, to support structured career development research investigating the impact of obesity and androgen receptor (AR) signaling on BRAF/MEK inhibitor (BRAF/MEKI) resistance in melanoma. Through this five-year award (completion date: April 30, 2031), the principal investigator will conduct research examining the "obesity paradox"—the clinical observation that obese males with melanoma demonstrate improved survival outcomes when treated with BRAF/MEKI compared to lean counterparts. The project deliverables include advanced in vivo modeling using diet-induced obesity mouse models, metabolomics analyses, and examination of human samples to define the effects of obesity, diet, and microbiome factors on melanoma metabolism and treatment resistance. The research plan comprises two specific aims: defining obesity's effect on melanoma metabolism, AR signaling, and BRAF/MEKI resistance through systemic investigation; and elucidating AR-mediated mechanisms of BRAF/MEKI resistance by examining how AR signaling alters endoplasmic reticulum stress response and cellular metabolism under treatment-induced metabolic stress. The award includes structured career development mentorship from Dr. Craig Slingluff and a distinguished advisory committee, positioning this K08 career development award to build the investigator's capacity for independent research leadership in surgical oncology and cancer therapeutics.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $291.5k | 3/30/26 |